Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.50 +1.35%

+$0.08 today

Market cap
$50.40M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

Returns on capital

Clene Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

148.8%

avg -751.9%

ROIC

-188.6%

avg -94.7%

ROA

-144.4%

avg -67.0%

Analysis

ROE is currently the strongest return metric at 148.8% versus its period average of -751.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Robert Etherington

Chief Executive Officer, President & DirectorUSD 547.24K59——

Mark G. Mortenson

Chief Science OfficerUSD 441.07K68——

Morgan R. Brown

Chief Financial OfficerUSD 324.16K5820.00K0.19%

Mary Anne Mcneil

Head of Human Resources————

Jerry Miraglia

General Counsel & Corporate Secretary————

Benjamin Greenberg

Head of Medical————

Michael T. Hotchkin

Chief Development Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 20, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$216,664.50

Sells

62

$5.78M

Net Transaction Value

−$5.56M

Net selling

Most Active

Ugwumba Chidozie

62 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 12, 26

Ugwumba Chidozie

Indirect

Sell$454.4K
May 11, 26

Ugwumba Chidozie

Indirect

Sell$149.7K
May 4, 26

Ugwumba Chidozie

Indirect

Sell$495.6K
May 1, 26

Ugwumba Chidozie

Indirect

Sell$34.8K
Apr 30, 26

Ugwumba Chidozie

Indirect

Sell$34.9K
Apr 29, 26

Ugwumba Chidozie

Indirect

Sell$68.5K
Apr 28, 26

Ugwumba Chidozie

Indirect

Sell$9.4K
Apr 21, 26

Ugwumba Chidozie

Indirect

Sell$376.7K
Apr 20, 26

Ugwumba Chidozie

Indirect

Sell$26.4K
Apr 17, 26

Ugwumba Chidozie

Indirect

Sell$161K

1–10 of 63

Summary

Insiders reported 1 buys worth $216,664.50 and 62 sells worth $5.78M over the last 12 months. That adds up to net selling of $5.56M. Ugwumba Chidozie was the most active insider with 62 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-24.9%
+392.8% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -24.9% over three years. Forward estimates point to Revenue at +392.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Clene Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CLNN's management, answered from reported figures.

Who manages CLNN?

Clene Inc. (CLNN) lists 7 active executives. The top listed executive is Mark G. Mortenson, Chief Science Officer.

Are CLNN insiders buying or selling?

Recent insider activity shows net selling of $7.83M.